Skip to main content
. 2022 May 31;70(6):1905–1917. doi: 10.4103/ijo.IJO_2030_21

Table 2.

Newer pharmacological therapy for Neurotrophic keratitis

Recombinant Human Nerve Growth Factor (rhNGF);
Cenegermin (Oxervate)
Re Genera Ting Agent (RGTA) polymer eye drops (Cacicol20®, OTR3, Paris, France)
Combination of topical substance P (SP) and insulin-like growth factor 1 (IGF-1)
Topical Insulin
Coenzyme Q10 and antisense oligonucleotide that suppresses connexin 43 expression
Semaphorins, Neurotrophins 3 and 4